Ulusal Romatoloji Dergisi / Journal of Turkish Society for Rheumatology
 
 
p-ISSN: 2651-2653
e-ISSN: 2651-2661
Editor-in-Chief
Haner Direskeneli
2018 Volume 10
 
 
Deomed Yayıncılık
 
 
 
Volume 10, Issue 1, June 2018
Page(s): 23-26
 
Case Report
Received: February 15, 2018; Accepted: February 18, 2018; Published online: June 1, 2018
doi:10.2399/raed.18.30592; Copyright © 2018 Turkish Society for Rheumatology
Abatacept in psoriatic arthritis: case reports
Gül Güzelant, Serdal Uğurlu (E-mail)
İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, İstanbul
Summary
Psoriatic arthritis (PsA) is a chronic and inflammatory arthropathy that may permanently damage joints. Nowadays it is reported that anti-TNF agents have good results in patients with inefficient response to conventional treatments. However, treatment with anti-TNF drugs is still problematic in patients who are resistant to or have any contraindications under treatment. In this group of patients, non-TNF biologic agents are started being used in daily practice. In this paper, we aimed to present three patients who had PsA diagnosis and abatacept treatment and to review the literature on this subject.
Keywords: Psoriatic arthritis, abatacept, psoriasis
 
 
Reklam
 
   
RAED Dergisi / RAED Journal

Türkiye Romatoloji Derneği (TRD) yayın organıdır. Deomed Yayıncılık tarafından yayımlanmaktadır. / Official Publication of the Rheumatology Society of Turkey (TRD). Published by Deomed Publishing. Copyright © 2018, TRD.
Creative Commons License
RAED Dergisi çevrimiçi (online) sürümünde yayımlanan akademik içeriğin kullanım hakları, ilgili içerikte tersi belirtilmediği sürece Deomed Yayıncılık tarafından Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) lisansı aracılığıyla bedelsiz sunulmaktadır. / Except where otherwise noted, academic content of this online version of the journal by Deomed Publishing is licensed under the terms of Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) License.